01609 天星醫療
STAR SPORTS MED
STAR SPORTS MED
| Register Close | 2026/04/29 IPO Closing in 5 Days |
| Listing Date | 2026/05/05 |
|
|
|
|
|
|
|
|
|
|
IPO Detail
COMPANY PROFILE
Star Sports Medicine Co. is a China-based medical device company specializing in clinical sports medicine solutions.
--
The Group is the fourth largest sports medicine implants and instruments provider, representing a market share of approximately 6.5% in China’s sports medicine implants and instruments market, and the largest domestic sports medicine implants and instruments provider in China, in terms of sales revenue in 2024, according to the report.
--
The Group offers holistic solutions for the treatment of injuries to soft tissues of rotator cuffs, ligaments and meniscus at shoulders, knees, hips, feet/ankles, elbows, and hands/wrist, as well as for the rehabilitation and prevention of sports-related injuries, leveraging its self-developed medical implants, active equipment, associated medical consumables and surgical instruments.
--
As of April 15, 2026, the Group’s product portfolio encompassed 63 products spanning medical implants, surgical equipment and associated medical consumables, as well as surgical instruments and regenerative repair products, it had 27 products with Class III medical device certificates and 25 with Class II medical device certificates. As of December 31, 2025, it had cumulatively sold over 2 million units of products.
BASIC INFORMATION
| Market | Hong Kong (Main Board) |
| Business Nature | Health Care |
| Major Business Area | China |
| Board Lot | 50 |
GLOBAL OFFERING
| No. of Offer Shares | 8.42M H shares |
| No. of International Offer Shares | 7.58M H shares |
| No. of HK Offer Shares | 0.84M H shares |
| Offer Price | $98.50 |
| Stock Code | 1609 |
| Sponsor(s) | CITIC Securities (Hong Kong) Limited, CCB International Capital Limited |
| Underwriter(s) | CLSA Limited, CCB International Capital Limited, China Galaxy International Securities (Hong Kong) Co., Limited, CMBC Securities Company Limited, Futu Securities International (Hong Kong) Limited, Open Securities Limited, Orient Securities (Hong Kong) Limited, Zheshang International Financial Holdings Co., Limited |
TIME TABLE
| Application Period | Apr 24 (Fri) - noon, Apr 29 (Wed) |
| Price Determination Date | -- |
| Result Announcement Date | On or before May 04 (Mon) |
| Result Announcement Date | On or before May 04 (Mon) |
| Result Announcement Date | On or before May 05 (Tue) |
| Dealings in Shares commence on | May 05, 2026. (Tue) |
Reallocation of Shares Offered
Sales Statistics (HKD)
| Offer Price | $98.50 |
| Capitalization (H Shares) | 5.40B |
| NAV / share ($) | $26.80 (Unaudited pro forma adj NAV / share) |
Use Of Proceeds
| Assuming the offer price being at HKD 98.5, the net proceeds raised would be HKD 758.40M, of which |
| 30% : Expand production capacity and enhance production efficiency |
| 35% : R&D efforts in line with patient-oriented product strategy |
| 25% : Used for commercialization, sales and marketing efforts to reinforce leadership in China and establish presence and brand image worldwide |
| 10% : Working capital |
Related Document
| Prospectus |  Chinese Version | English Version |
| Remark： | The above information is referenced from the prospectus. |
| All data is calculated from the non- exercise rights(if applicable). |
Name︰
--
--
--
Subscription --
Result Announcement --
Listing --Offer Price︰--
| Currency | : |
| Listing Price | : |
| Board Lot | : |
| Admission Fee* |
: |
| Subscribing Lot | : |
| Subscribing Fee | : |
| Subscribing Amount | : |
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015% (i.e. 1.0077% in total).